Monday, 30 January 2017 13:55

Pioglitazone-Containing Medicines And Their Increased Risk Of Bladder Cancer

Rate this item
(0 votes)

The attention of the Agency has been drawn to recent warning by the US Food and Drug Administration concerning some Medicines containing Pioglitazone (They include Actos, Actoplus Met, Actopus Met XR, Duetact, and Oseni) which increases the risk of bladder cancer in patients who have Type 2 diabetes as its often recommended for them.

Pioglitazone is a drug approved to improve blood sugar control, along with diet and exercise, in adults with type 2 diabetes. This Drug is in a class of medications called thiazolidinediones. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels. It is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated).

POSSIBLE RISK ASSOCIATED WITH THIS DRUG:

Patients with type 2 diabetes may experience the following symptoms after using Pioglitazone which may be due to bladder cancer and they are as follows;

Blood or a red color in the urine

New or worsening urge to urinate

Pain when urinating

DETAILS OF THE PRODUCT:

Product names:              Actos

                                                Actoplus Met (containing Metformin, Pioglitazone)

                                                Actoplus Met XR (containing Metformin, Pioglitazone)

                                                Duetact (containing Glimepiride, Pioglitazone)

                                                Oseni (Alogliptin/pioglitazone )

Product Manufacturer: The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland.

Manufacturing Date:       Unknown

Expiry date:                   Unknown

Health care professionals are advised not to use pioglitazone in patients with active bladder cancer, and should carefully consider the benefits and risks before using Pioglitazone in patients with a history of bladder cancer.

Patients are advised to contact their health care professionals if they experience any signs or symptoms after starting Pioglitazone, as these may be due to bladder cancer:

The Agency also encourages healthcare professionals and patients to report adverse events or side effects related to the use of these products to NAFDAC PRASCOR (20543-Toll free from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC........Safeguarding the health of the nation!!!

Read 8595 times Last modified on Monday, 30 January 2017 14:04

CORPORATE LINKS